CI

At a glance

ClinicalIndex Comparison Record
Phase 4Completed· 15 enrolled
Drug / intervention
Azithromycin Dihydratedrug
Likely dose
Azithromycin Dihydrate 250 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01109160
NCT01109160Phase 4Completed
CompareCT.gov

A Prospective, Open-label Study of Azithromycin for Lymphocytic Bronchiolitis/Bronchitis After Lung Transplantation

KU Leuven·interventional·Posted Apr 23, 2010·Updated Jul 4, 2013

In Brief

A Phase 4 clinical trial evaluating Azithromycin Dihydrate for Lymphocytic Bronchi(Oli)Tis Post-lung Transplantation. Completed, enrolled 15 participants across 1 site.

Detailed Summary

This study investigates the role of azithromycin treatment for lymphocytic bronchitis/bronchiolitis after lung transplantation.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphocytic Bronchi(Oli)Tis Post-lung Transplantation
CountriesBelgium
CollaboratorsFund for Scientific Research, Flanders, Belgium

Timeline

Phase 4CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedApr 23, 2010
Enrollment StartApr 1, 2010
Primary CompletionOct 1, 2012
Study CompletionJul 1, 2013
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 16.2 years ago

Interventions

Azithromycin Dihydratedrug

Add-on of study-drug (azithromycin) to 'standard of care' at diagnosis of lymphocytic bronchi(oli)tis. Study-drug regime: 250 mg daily for 5 days, followed by 250 mg every other day until the end of the study-period (6 months treatment).